SCHEMBL650293

SCHEMBL650293

O=S(=O)(NC1Cc2cc(-c3ccc(OCc4ccccc4)c(F)c3)ccc2N(Cc2ccccc2)C1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
S1PR5 Q9H228 1/20 0.41
ERN1 O75460 1/20 0.39
UCHL1 P09936 1/20 0.38
USP30 Q70CQ3 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
SCN9A Q15858 1/20 0.37
NR1H2 P55055 4/20 0.36
IDH2 P48735 1/20 0.36
NAAA Q02083 1/20 0.36
CCR3 P51677 1/20 0.35
HTR7 P34969 5/20 0.35
HTR1A P08908 4/20 0.35
CTSA P10619 1/20 0.35
HTT P42858 1/20 0.35
DRD2 P14416 2/20 0.35
HTR6 P50406 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652680 0.86 FNTA (0.47) FNTAFNTBMTNR1AMTNR1BNR1H2
SCHEMBL651273 0.85 FNTA (0.49) FNTAFNTBUCHL1MTNR1AMTNR1B
SCHEMBL651315 0.85 FNTA (0.49) FNTAFNTBUCHL1MTNR1AMTNR1B
SCHEMBL651274 0.85 FNTA (0.49) FNTAFNTBUCHL1MTNR1AMTNR1B
SCHEMBL1260557 0.85 FNTA (0.52) FNTAFNTBUCHL1USP30MTNR1A
SCHEMBL650121 0.85 FNTA (0.52) FNTAFNTBUCHL1USP30MTNR1A
SCHEMBL650120 0.85 FNTA (0.52) FNTAFNTBUCHL1USP30MTNR1A
SCHEMBL651316 0.84 FNTA (0.48) FNTAFNTBMTNR1AMTNR1BNR1H2
SCHEMBL651456 0.81 FNTA (0.53) FNTAFNTBUCHL1USP30MTNR1A
SCHEMBL650563 0.81 FNTA (0.47) FNTAFNTBMTNR1AMTNR1BNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US claimed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US claimed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US claimed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US disclosed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885S1PR5 467/4885
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885S1PR5 467/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 FNTA 1368/4885FNTB 2071/4885S1PR5 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.